- ARIAD Pharmaceuticals (NASDAQ:ARIA) Q1 results: Revenues: $35.6M (+48.3%); R&D Expense: $44.1M (+11.9%); SG&A: $36M (+7.1%); Net Loss: ($53.8M) (-2.1%); Loss Per Share: ($0.28) (unch); Non-GAAP Loss Per Share: ($0.23) (+4.2%); Quick Assets: $168.3M (-30.5%); CF Ops: ($65.1M) (-29.7%).
- 2016 Guidance: Iclusig Net Product & Royalty Revenue: $170M - 180M from $190M - 200M; R&D Expense: $175M - 180M; SG&A Expense: $120M - 125M; Cash at year end: $280M - 290M.